Kymera Therapeutics KYMR 深 滬
等待開盤 08-10 09:30:00 美东时间
107.52
+1.110
+1.04%
華盛通- 最 高108.12
- 今 開106.61
- 成交量 46.36万股
- 最 低 104.78
- 昨 收 106.41
- 總市值 89.40亿
- 52周最高 130.05
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 39.84
- 委 比 -98.53%
- 總股本 8315.06万
- 歷史最高 130.05
- 量 比 0.81
- 振 幅 3.14%
- 歷史最低 9.60
- 每 手 1
- 風險率 19.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
08-06 22:00
财报速睇 | Kymera Therapeutics 2026财年Q2营收0.65亿美元，同比增长466.4%；归母净利润亏损0.61亿美元，同比亏损缩窄20.1%
华盛资讯8月5日讯，Kymera Therapeutics公布2026财年Q2业绩，公司Q2营收0.65亿美元，同比增长466.4%，归母净利润亏损0.61亿美元，同比亏损缩窄20.1%。
08-05 19:41
Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $65.000 mi...
08-05 19:04
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst David Hoang initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR) wit...
07-30 23:41
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.
07-28 19:06
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Kymera Therapeutics appoints Dr. Terence Rooney as Chief Medical Officer to lead its clinical development strategy for oral immunology therapies. Dr. Rooney, with extensive experience in immunology drug development, succeeds Dr. Jared Gollob, who is retiring after eight years with the company. Kymera focuses on advancing oral small molecule degraders for immunological diseases, aiming to address treatment gaps and improve patient outcomes.
07-27 20:01
ClearBridge Small-Cap Growth Strategy adds new positions, exits others
ClearBridge Small-Cap Growth Strategy returned 21% in Q2 2026, underperforming the Russell 2000 Growth Index, which gained 26% during the same period. During Q2 2026, the strategy initiated 13 new pos...
07-20 22:08
